RARE vs VRCA · rev $350.0M vs rev $10.9M
Ultragenyx (RARE) versus Verrica Pharmaceuticals Inc (VRCA) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
Verrica Pharmaceuticals Inc (VRCA) is a biotechnology company listed on US.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
Latest reported VRCA revenue for 2026-06-30 was $10.9M. Net income was -$22.8M. VRCA currently screens at market cap $79.7M.
RARE currently screens at market cap $2.79B. VRCA currently screens at market cap $79.7M.
Not investment advice. Open the RARE and VRCA stock pages for the full models.
Not investment advice.